Beitelin (Ifupinostat) – R/R DLBCL | HongKong DengYue Medicine

  • Generic Name/Brand Name: ​Ifupinostat / Beitelin®
  • Indications: R/R DLBCL
  • Dosage Form: ​Injection
  • Specification: 20.6 mg × 1 vial/box

Ifupinostat Application Scope

It is indicated for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) who have previously received at least two lines of systemic therapy. This targeted therapy offers a novel option for patients with limited treatment choices, aiming to inhibit tumor growth and improve clinical outcomes in this difficult-to-treat population.

beitelin ifupinostat
beitelin ifupinostat

Ifupinostat Characteristics

  • Ingredients: Ifupinostat Hydrochloride

  • Properties:​ First-in-class dual HDAC & PI3Kα inhibitor

  • Packaging Specification:​ 20.6 mg (lyophilized powder for injection)

  • Storage:​ 2–8 °C, protect from light, do not freeze

  • Expiry Date: Refer to product label (commonly 24–36 months)

  • Executive Standard: ​NMPA-approved chemical drug (Class 1) standard

  • Approval Number: NMPA conditional approval (2025)

  • Date of Revision: See the latest package insert

  • Manufacturer: Guangzhou BeBetter Medicine Co., Ltd.

Guidelines for the Use of xxx

  • Dosage and Administration:

    • Recommended Dose: 18.5 mg/m²

    • Administration: Days 1, 3, 5, 8, 10, 12 of each cycle until progression or intolerance

    • Missed Dose:​ Follow the physician’s instructions; do not double-dose

  • Adverse Reactions:

    • Common Adverse Reactions:

      • Thrombocytopenia

      • anemia

      • neutropenia

      • fatigue

      • nausea

    • Serious Adverse Reactions:

      • Severe cytopenia

      • infection

      • bleeding

  • Contraindications: Hypersensitivity to components, severe uncorrected myelosuppression

  • Precautions:

    • Monitor CBC
    • liver/renal function
    • infection signs
    • use contraception during and after treatment

Ifupinostat Interactions

  • It may interact with strong CYP enzyme inhibitors or inducers, which can affect its metabolism and plasma levels.
  • Additionally, concurrent use with other myelosuppressive or anticoagulant medications can increase the risk of hematologic toxicity or bleeding.
  • Close monitoring of blood counts and careful management of co-administered drugs are recommended to ensure patient safety.

 

Note:

  • If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
  •  This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.
Contact Us
Contact Form Demo